Lamivudine for the treatment of chronic hepatitis B

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 3, 2002, Pages 329-339

  Sokal, Etienne ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Adolescence; Children; Cirrhosis; HBeAg; HBsAg; Hepatitis B; Interferon; Lamivudine; Nucleotide analogue; Pre core mutant; Treatment; Viral hepatitis; YMDD mutant

Indexed keywords

ALPHA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LIVER ENZYME;

ADULT; ALOPECIA; ANTIVIRAL ACTIVITY; APPETITE DISORDER; ARTICLE; CHILD; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; GRAFT INFECTION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER FUNCTION; LIVER TRANSPLANTATION; NEUTROPENIA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SAFETY; SEROCONVERSION; TREATMENT INDICATION; VIRUS CARRIER; VIRUS MUTATION;

ANTIVIRAL AGENTS; CHILD; CLINICAL TRIALS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION;

EID: 0036194619     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.3.329     Document Type: Article

References (56)

1. Fact sheet: Hepatitis B
2. Liver transplantation in European patients with the hepatitis B surface antigen
3. Hepatitis B virus infection and hepatocellular carcinoma: Molecular genetics and clinical perspectives
4. Horizontal transmission of hepatitis B virus
5. Horizontal transmission of hepatitis B from children to adoptive parents
6. Hepatitis B in a Belgian institution for mentally retarded patients: An epidemiological study
7. Molecular characterisation and sequence stability of the hepatitis B virus surface gene in children treated with Interferon
8. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
9. Management of hepatitis B: 2000 - Summary of a workshop
10. Clinical relevance of hepatitis B viral mutations
11. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B
12. Lamivudine as initial treatment for chronic hepatitis B in the United States
13. A dose-ranging study of the pharmacokinetics, safety and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B
14. A one year trial of lamivudine for chronic hepatitis B
15. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
16. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
17. An international double-blind placebo-controlled trial of lamivudine in 286 children with chronic hepatitis B
18. Pre-therapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during Lamivudine therapy in patients with chronic hepatitis B
19. A follow on study in children with chronic hepatitis B who completed a placebo controlled lamivudine study - A six months interim analysis
20. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
21. Efficacy and safety of lamivudine treatment of Chinese patients with chronic hepatitis B
22. Interferon-alpha treatment of chronic hepatitis B in childhood: A consensus advice based on experience in European children
23. Faut-il traiter l'hépatite B de l'enfant?
24. Is liver biopsy needed in children with chronic hepatitis?
25. Update on prevention and treatment of viral hepatitis in children
26. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicentre, randomized trial
27. Long-term remission of chronic hepatitis B after alpha-interferon therapy
28. Interferon alfa therapy for chronic hepatitis B in children: A multinational randomized controlled trial
29. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate motif mutation of hepatitis B virus after long-term lamivudine therapy
30. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation
31. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study
32. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver
33. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort
34. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
35. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
36. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
37. A multicentre United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B
38. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis
39. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in children
40. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
41. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
42. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus
43. DS. Precore stop codon mutant in chronic hepatitis B virus infection in children: Its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen
44. Failure of neonatal hepatitis B vaccination: The role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates
45. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viraemic chronic hepatitis B patients
46. Doctor-to-patient transmission of viral hepatitis B: Is it a problem, is there a solution?
47. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy
48. Long-term therapy of chronic hepatitis B with lamivudine
49. The effect of longer duration of harbouring lamivudine resistant hepatitis B virus (YMDD mutants) on liver histology during three years Lamivudine therapy in Chinese patients
50. Current pharmacotherapy for hepatitis B infection
51. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children
52. No increase in demyelinating diseases after hepatitis B vaccination
53. Hepatitis B vaccination and the risk of multiple sclerosis
54. Vaccinations and the risk of relapse in multiple sclerosis
55. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
56. Long-term effect of alpha interferon in children with chronic hepatitis B